All In Biotech

Drug Trial Radar · NCT05093907

A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer

An Open-label, Single Center, Phase I/II Clinical Trial to Assess the Maximum Tolerated Dose, Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer Refractory or Intolerant to Standard of Care

Last checked: Nov 19, 2026Latest source record: Mar 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

27

Planned (sponsor's estimate)

Start

Aug 31, 2021

Primary completion

Nov 30, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
BeyondBio Inc.Industry
Sponsor type
Industry
First posted
Oct 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2 study to evaluate the maximum tolerated dose, safety and efficacy of BEY1107 in combination with capecitabine in patients with metastatic colorectal cancer refractory or intolerant to standard of care (SoC).

Conditions

  • Metastatic Colorectal Cancer

Interventions

  • BEY1107Drug

    Administer once daily, PO, 3-week continuous dose.

  • CapecitabineCombination product

    Administer twice daily, PO, 2-week continuous dose, followed by 1-week rest period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose(MTD) assessed by investigator following administration of BEY1107 in combination with CapecitabineTime frame: From baseline up to disease progression, approximately 54 weeks
  2. Objective Response Rate(ORR)(Phase 2) assessed by investigator following administration of BEY1107 in combination with CapecitabineTime frame: From baseline up to disease progression, approximately 54 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Hospial

    Seoul, Jongro-go, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.